-
1
-
-
84881551802
-
New cyclophilin inhibitors unrelated to cyclosporine potently inhibit HCV replication and revert HCV-induced mitochondrial dysfunction
-
A. Ahmed-Belkacem, L. Colliandre, N. Ahnou, N. Lerat, Y. Bessin, P. Barthe, W. Bourget, D. Douguet, J.F. Guichou, and J.M. Pawlotsky New cyclophilin inhibitors unrelated to cyclosporine potently inhibit HCV replication and revert HCV-induced mitochondrial dysfunction Hepatology 56 2012 1067A 1068A
-
(2012)
Hepatology
, vol.56
-
-
Ahmed-Belkacem, A.1
Colliandre, L.2
Ahnou, N.3
Lerat, N.4
Bessin, Y.5
Barthe, P.6
Bourget, W.7
Douguet, D.8
Guichou, J.F.9
Pawlotsky, J.M.10
-
2
-
-
84870030071
-
Alisporivir (Alv) plus peg-interferon/ribavirin (Pr) in Hcv G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with Pr
-
A. Alberti, W.L. Chuang, R. Flisiak, G. Mazzella, A. Horban, T. Goeser, P. Calistru, M. Buti, G. Davis, Y. Gong, C. Avila, and J.H. Kao Alisporivir (Alv) plus peg-interferon/ribavirin (Pr) in Hcv G1 treatment-experienced patients achieves primary endpoint with superior efficacy at treatment week 12 compared to retreatment with Pr Journal of Hepatology 56 2012 S553 S554
-
(2012)
Journal of Hepatology
, vol.56
-
-
Alberti, A.1
Chuang, W.L.2
Flisiak, R.3
Mazzella, G.4
Horban, A.5
Goeser, T.6
Calistru, P.7
Buti, M.8
Davis, G.9
Gong, Y.10
Avila, C.11
Kao, J.H.12
-
3
-
-
4644309196
-
The functions of animal microRNAs
-
V. Ambros The functions of animal microRNAs Nature 431 2004 350 355
-
(2004)
Nature
, vol.431
, pp. 350-355
-
-
Ambros, V.1
-
4
-
-
84867772865
-
Cyclophilin involvement in the replication of hepatitis C virus and other viruses
-
J. Baugh, and P. Gallay Cyclophilin involvement in the replication of hepatitis C virus and other viruses Biological Chemistry 393 2012 579 587
-
(2012)
Biological Chemistry
, vol.393
, pp. 579-587
-
-
Baugh, J.1
Gallay, P.2
-
5
-
-
66149128094
-
Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication
-
K.L. Berger, J.D. Cooper, N.S. Heaton, R. Yoon, T.E. Oakland, T.X. Jordan, G. Mateu, A. Grakoui, and G. Randall Roles for endocytic trafficking and phosphatidylinositol 4-kinase III alpha in hepatitis C virus replication Proceedings of the National Academy of Sciences of the United States of America 106 2009 7577 7582
-
(2009)
Proceedings of the National Academy of Sciences of the United States of America
, vol.106
, pp. 7577-7582
-
-
Berger, K.L.1
Cooper, J.D.2
Heaton, N.S.3
Yoon, R.4
Oakland, T.E.5
Jordan, T.X.6
Mateu, G.7
Grakoui, A.8
Randall, G.9
-
6
-
-
84861658289
-
Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7
-
A. Boonstra, B.S. Liu, Z.M.A. Groothuismink, J.F. Bergmann, J. de Bruijne, D.M. Hotho, B.E. Hansen, A.A. van Vliet, J.V. de Rooij, S.P. Fletcher, L.A. Bauman, M. Rahimy, J.R. Appleman, J.L. Freddo, H.W. Reesink, R.J. de Knegt, and H.L.A. Janssen Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via Toll-like receptor 7 Antiviral Therapy 17 2012 657 667
-
(2012)
Antiviral Therapy
, vol.17
, pp. 657-667
-
-
Boonstra, A.1
Liu, B.S.2
Groothuismink, Z.M.A.3
Bergmann, J.F.4
De Bruijne, J.5
Hotho, D.M.6
Hansen, B.E.7
Van Vliet, A.A.8
De Rooij, J.V.9
Fletcher, S.P.10
Bauman, L.A.11
Rahimy, M.12
Appleman, J.R.13
Freddo, J.L.14
Reesink, H.W.15
De Knegt, R.J.16
Janssen, H.L.A.17
-
7
-
-
0037188776
-
History of the discovery of cyclosporin and of its early pharmacological development
-
J.F. Borel History of the discovery of cyclosporin and of its early pharmacological development Wiener klinische Wochenschrift 114 2002 433 437
-
(2002)
Wiener Klinische Wochenschrift
, vol.114
, pp. 433-437
-
-
Borel, J.F.1
-
9
-
-
67650550814
-
The isomerase active site of cyclophilin A is critical for hepatitis C virus replication
-
U. Chatterji, M. Bobardt, S. Selvarajah, F. Yang, H. Tang, N. Sakamoto, G. Vuagniaux, T. Parkinson, and P. Gallay The isomerase active site of cyclophilin A is critical for hepatitis C virus replication The Journal of Biological Chemistry 284 2009 16998 17005
-
(2009)
The Journal of Biological Chemistry
, vol.284
, pp. 16998-17005
-
-
Chatterji, U.1
Bobardt, M.2
Selvarajah, S.3
Yang, F.4
Tang, H.5
Sakamoto, N.6
Vuagniaux, G.7
Parkinson, T.8
Gallay, P.9
-
10
-
-
77951046665
-
HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors
-
U. Chatterji, P. Lim, M.D. Bobardt, S. Wieland, D.G. Cordek, G. Vuagniaux, F. Chisari, C.E. Cameron, P. Targett-Adams, T. Parkinson, and P.A. Gallay HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors Journal of Hepatology 53 2010 50 56
-
(2010)
Journal of Hepatology
, vol.53
, pp. 50-56
-
-
Chatterji, U.1
Lim, P.2
Bobardt, M.D.3
Wieland, S.4
Cordek, D.G.5
Vuagniaux, G.6
Chisari, F.7
Cameron, C.E.8
Targett-Adams, P.9
Parkinson, T.10
Gallay, P.A.11
-
11
-
-
78149434641
-
DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A
-
L. Coelmont, X. Hanoulle, U. Chatterji, C. Berger, J. Snoeck, M. Bobardt, P. Lim, I. Vliegen, J. Paeshuyse, G. Vuagniaux, A.M. Vandamme, R. Bartenschlager, P. Gallay, G. Lippens, and J. Neyts DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A Plos One 5 2010 e13687
-
(2010)
Plos One
, vol.5
, pp. 13687
-
-
Coelmont, L.1
Hanoulle, X.2
Chatterji, U.3
Berger, C.4
Snoeck, J.5
Bobardt, M.6
Lim, P.7
Vliegen, I.8
Paeshuyse, J.9
Vuagniaux, G.10
Vandamme, A.M.11
Bartenschlager, R.12
Gallay, P.13
Lippens, G.14
Neyts, J.15
-
13
-
-
84881544521
-
TVB-2640, a novel anti-HCV agent, safely causes sustained host-target inhibition in vivo
-
M. Evanchik, H.Y. Cai, Q.S. Feng, L. Hu, R. Johnson, G. Kemble, Y. Kosaka, J. Lai, J.D. Oslob, M. Sivaraja, S. Tep, H.B. Yan, C.A. Zaharia, and R. McDowell TVB-2640, a novel anti-HCV agent, safely causes sustained host-target inhibition in vivo Hepatology 56 2012 1066A 1067A
-
(2012)
Hepatology
, vol.56
-
-
Evanchik, M.1
Cai, H.Y.2
Feng, Q.S.3
Hu, L.4
Johnson, R.5
Kemble, G.6
Kosaka, Y.7
Lai, J.8
Oslob, J.D.9
Sivaraja, M.10
Tep, S.11
Yan, H.B.12
Zaharia, C.A.13
McDowell, R.14
-
14
-
-
84861866572
-
The mechanics of miRNA-mediated gene silencing: A look under the hood of miRISC
-
M.R. Fabian, and N. Sonenberg The mechanics of miRNA-mediated gene silencing: a look under the hood of miRISC Nature Structural and Molecular Biology 19 2012 586 593
-
(2012)
Nature Structural and Molecular Biology
, vol.19
, pp. 586-593
-
-
Fabian, M.R.1
Sonenberg, N.2
-
15
-
-
78149361253
-
Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A
-
F. Fernandes, I.U. Ansari, and R. Striker Cyclosporine inhibits a direct interaction between cyclophilins and hepatitis C NS5A Plos One 5 2010 e9815
-
(2010)
Plos One
, vol.5
, pp. 9815
-
-
Fernandes, F.1
Ansari, I.U.2
Striker, R.3
-
16
-
-
66149129922
-
The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients
-
R. Flisiak, S.V. Feinman, M. Jablkowski, A. Horban, W. Kryczka, M. Pawlowska, J.E. Heathcote, G. Mazzella, C. Vandelli, V. Nicolas-Metral, P. Grosgurin, J.S. Liz, P. Scalfaro, H. Porchet, and R. Crabbe The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naive hepatitis C patients Hepatology 49 2009 1460 1468
-
(2009)
Hepatology
, vol.49
, pp. 1460-1468
-
-
Flisiak, R.1
Feinman, S.V.2
Jablkowski, M.3
Horban, A.4
Kryczka, W.5
Pawlowska, M.6
Heathcote, J.E.7
Mazzella, G.8
Vandelli, C.9
Nicolas-Metral, V.10
Grosgurin, P.11
Liz, J.S.12
Scalfaro, P.13
Porchet, H.14
Crabbe, R.15
-
17
-
-
40949117600
-
The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
-
R. Flisiak, A. Horban, P. Gallay, M. Bobardt, S. Selvarajah, A. Wiercinska-Drapalo, E. Siwak, I. Cielniak, J. Higersberger, J. Kierkus, C. Aeschlimann, P. Grosgurin, V. Nicolas-Metral, J.M. Dumont, H. Porchet, R. Crabbe, and P. Scalfaro The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus Hepatology 47 2008 817 826
-
(2008)
Hepatology
, vol.47
, pp. 817-826
-
-
Flisiak, R.1
Horban, A.2
Gallay, P.3
Bobardt, M.4
Selvarajah, S.5
Wiercinska-Drapalo, A.6
Siwak, E.7
Cielniak, I.8
Higersberger, J.9
Kierkus, J.10
Aeschlimann, C.11
Grosgurin, P.12
Nicolas-Metral, V.13
Dumont, J.M.14
Porchet, H.15
Crabbe, R.16
Scalfaro, P.17
-
18
-
-
79960446187
-
Once Daily Alisporivir (Deb025) Plus Pegifnalfa2a/Ribavirin Results in Superior Sustained Virologic Response (Svr24) in Chronic Hepatitis C Genotype 1 Treatment Naive Patients
-
S2-S2
-
R. Flisiak, J.M. Pawlotsky, R. Crabbe, P.I. Calistru, W. Kryczka, D. Haussinger, G. Mazzella, M. Romero-Gomez, D. Purcea, G. Vuagniaux, W. Bao, C. Avila, and S. Zeuzem Once Daily Alisporivir (Deb025) Plus Pegifnalfa2a/Ribavirin Results in Superior Sustained Virologic Response (Svr24) in Chronic Hepatitis C Genotype 1 Treatment Naive Patients Journal of Hepatology 54 2011 S2-S2
-
(2011)
Journal of Hepatology
, vol.54
-
-
Flisiak, R.1
Pawlotsky, J.M.2
Crabbe, R.3
Calistru, P.I.4
Kryczka, W.5
Haussinger, D.6
Mazzella, G.7
Romero-Gomez, M.8
Purcea, D.9
Vuagniaux, G.10
Bao, W.11
Avila, C.12
Zeuzem, S.13
-
19
-
-
84874030693
-
Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication
-
J. Friborg, S. Levine, C.Q. Chen, A.K. Sheaffer, S. Chaniewski, S. Voss, J.A. Lemm, and F. McPhee Combinations of Lambda Interferon with Direct-Acting Antiviral Agents Are Highly Efficient in Suppressing Hepatitis C Virus Replication Antimicrobial Agents and Chemotheraphy 57 2013 1312 1322
-
(2013)
Antimicrobial Agents and Chemotheraphy
, vol.57
, pp. 1312-1322
-
-
Friborg, J.1
Levine, S.2
Chen, C.Q.3
Sheaffer, A.K.4
Chaniewski, S.5
Voss, S.6
Lemm, J.A.7
McPhee, F.8
-
20
-
-
84882886054
-
Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines
-
J. Friborg, B. Lin, C. Chen, and F. McPhee Isolation and characterization of interferon lambda-resistant hepatitis C virus replicon cell lines Virology 444 2013 384 393
-
(2013)
Virology
, vol.444
, pp. 384-393
-
-
Friborg, J.1
Lin, B.2
Chen, C.3
McPhee, F.4
-
21
-
-
84873978406
-
Profile of alisporivir and its potential in the treatment of hepatitis C
-
P.A. Gallay, and K. Lin Profile of alisporivir and its potential in the treatment of hepatitis C Drug Design, Development and Therapy 7 2013 105 115
-
(2013)
Drug Design, Development and Therapy
, vol.7
, pp. 105-115
-
-
Gallay, P.A.1
Lin, K.2
-
24
-
-
65449136656
-
American Association for the Study of Liver, D., Diagnosis, management, and treatment of hepatitis C: An update
-
M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff American Association for the Study of Liver, D., Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
-
(2009)
Hepatology
, vol.49
, pp. 1335-1374
-
-
Ghany, M.G.1
Strader, D.B.2
Thomas, D.L.3
Seeff, L.B.4
-
26
-
-
33645911783
-
Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811
-
K. Goto, K. Watashi, T. Murata, T. Hishiki, M. Hijikata, and K. Shimotohno Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811 Biochemical and Biophysics Research Communication 343 2006 879 884
-
(2006)
Biochemical and Biophysics Research Communication
, vol.343
, pp. 879-884
-
-
Goto, K.1
Watashi, K.2
Murata, T.3
Hishiki, T.4
Hijikata, M.5
Shimotohno, K.6
-
27
-
-
79955536124
-
Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family
-
M.A. Gregory, M. Bobardt, S. Obeid, U. Chatterji, N.J. Coates, T. Foster, P. Gallay, P. Leyssen, S.J. Moss, J. Neyts, M. Nur-e-Alam, J. Paeshuyse, M. Piraee, D. Suthar, T. Warneck, M.Q. Zhang, and B. Wilkinson Preclinical characterization of naturally occurring polyketide cyclophilin inhibitors from the sanglifehrin family Antimicrobial Agents and Chemotherapy 55 2011 1975 1981
-
(2011)
Antimicrobial Agents and Chemotherapy
, vol.55
, pp. 1975-1981
-
-
Gregory, M.A.1
Bobardt, M.2
Obeid, S.3
Chatterji, U.4
Coates, N.J.5
Foster, T.6
Gallay, P.7
Leyssen, P.8
Moss, S.J.9
Neyts, J.10
Nur-E-Alam, M.11
Paeshuyse, J.12
Piraee, M.13
Suthar, D.14
Warneck, T.15
Zhang, M.Q.16
Wilkinson, B.17
-
28
-
-
84867027382
-
All for one, one for all: New combinatorial RNAi therapies combat hepatitis C virus evolution
-
D. Grimm All for one, one for all: new combinatorial RNAi therapies combat hepatitis C virus evolution Molecular Therapy: The Journal of the American Society of Gene Therapy 20 2012 1661 1663
-
(2012)
Molecular Therapy: The Journal of the American Society of Gene Therapy
, vol.20
, pp. 1661-1663
-
-
Grimm, D.1
-
29
-
-
67649412015
-
Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B
-
X. Hanoulle, A. Badillo, J.M. Wieruszeski, D. Verdegem, I. Landrieu, R. Bartenschlager, F. Penin, and G. Lippens Hepatitis C virus NS5A protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins A and B The Journal of Biological Chemistry 284 2009 13589 13601
-
(2009)
The Journal of Biological Chemistry
, vol.284
, pp. 13589-13601
-
-
Hanoulle, X.1
Badillo, A.2
Wieruszeski, J.M.3
Verdegem, D.4
Landrieu, I.5
Bartenschlager, R.6
Penin, F.7
Lippens, G.8
-
30
-
-
84879689088
-
25 years of interferon-based treatment of chronic hepatitis C: An epoch coming to an end
-
M.H. Heim 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end Nature Reviews Immunology 13 2013 535 542
-
(2013)
Nature Reviews Immunology
, vol.13
, pp. 535-542
-
-
Heim, M.H.1
-
31
-
-
84869112137
-
A Unique Therapy for Hcv Inhibits Microrna-122 in Humans and Results in Hcv Rna Suppression in Chronically Infected Chimpanzees: Results from Primate and First-in-Human Studies
-
12A-12A
-
E.S. Hildebrandt-Eriksen, Y.Z. Bagger, T.B. Knudsen, A. Petri, R. Persson, H.M. Boergesen, J.G. McHulchison, and A.A. Levin A Unique Therapy for Hcv Inhibits Microrna-122 in Humans and Results in Hcv Rna Suppression in Chronically Infected Chimpanzees: Results from Primate and First-in-Human Studies Hepatology 50 2009 12A-12A
-
(2009)
Hepatology
, vol.50
-
-
Hildebrandt-Eriksen, E.S.1
Bagger, Y.Z.2
Knudsen, T.B.3
Petri, A.4
Persson, R.5
Boergesen, H.M.6
McHulchison, J.G.7
Levin, A.A.8
-
32
-
-
84862697734
-
The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection
-
S. Hopkins, B. DiMassimo, P. Rusnak, D. Heuman, J. Lalezari, A. Sluder, B. Scorneaux, S. Mosier, P. Kowalczyk, Y. Ribeill, J. Baugh, and P. Gallay The cyclophilin inhibitor SCY-635 suppresses viral replication and induces endogenous interferons in patients with chronic HCV genotype 1 infection Journal of Hepatology 57 2012 47 54
-
(2012)
Journal of Hepatology
, vol.57
, pp. 47-54
-
-
Hopkins, S.1
Dimassimo, B.2
Rusnak, P.3
Heuman, D.4
Lalezari, J.5
Sluder, A.6
Scorneaux, B.7
Mosier, S.8
Kowalczyk, P.9
Ribeill, Y.10
Baugh, J.11
Gallay, P.12
-
33
-
-
75749110945
-
SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro
-
S. Hopkins, B. Scorneaux, Z. Huang, M.G. Murray, S. Wring, C. Smitley, R. Harris, F. Erdmann, G. Fischer, and Y. Ribeill SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro Antimicrob Agents Chemother 54 2010 660 672
-
(2010)
Antimicrob Agents Chemother
, vol.54
, pp. 660-672
-
-
Hopkins, S.1
Scorneaux, B.2
Huang, Z.3
Murray, M.G.4
Wring, S.5
Smitley, C.6
Harris, R.7
Erdmann, F.8
Fischer, G.9
Ribeill, Y.10
-
34
-
-
34250337631
-
Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins
-
H. Huang, F. Sun, D.M. Owen, W. Li, Y. Chen, M. Gale Jr., and J. Ye Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins Proceedings of the National Academy of Sciences of the United States of America 104 2007 5848 5853
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, pp. 5848-5853
-
-
Huang, H.1
Sun, F.2
Owen, D.M.3
Li, W.4
Chen, Y.5
Gale, Jr.M.6
Ye, J.7
-
35
-
-
84876315023
-
Hepatitis C Virus Replication Is Modulated by the Interaction of Nonstructural Protein NS5B and Fatty Acid Synthase
-
J.T. Huang, C.P. Tseng, M.H. Liao, S.C. Lu, W.Z. Yeh, N. Sakamoto, C.M. Chen, and J.C. Cheng Hepatitis C Virus Replication Is Modulated by the Interaction of Nonstructural Protein NS5B and Fatty Acid Synthase Journal of Virology 87 2013 4994 5004
-
(2013)
Journal of Virology
, vol.87
, pp. 4994-5004
-
-
Huang, J.T.1
Tseng, C.P.2
Liao, M.H.3
Lu, S.C.4
Yeh, W.Z.5
Sakamoto, N.6
Chen, C.M.7
Cheng, J.C.8
-
36
-
-
0038102952
-
Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: Controlled trial
-
K. Inoue, K. Sekiyama, M. Yamada, T. Watanabe, H. Yasuda, and M. Yoshiba Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial Journal of Gastroenterology 38 2003 567 572
-
(2003)
Journal of Gastroenterology
, vol.38
, pp. 567-572
-
-
Inoue, K.1
Sekiyama, K.2
Yamada, M.3
Watanabe, T.4
Yasuda, H.5
Yoshiba, M.6
-
37
-
-
17844375433
-
Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease
-
K. Inoue, and M. Yoshiba Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease Transplantation Proceedings 37 2005 1233 1234
-
(2005)
Transplantation Proceedings
, vol.37
, pp. 1233-1234
-
-
Inoue, K.1
Yoshiba, M.2
-
38
-
-
33646194456
-
Diverse effects of cyclosporine on hepatitis C virus strain replication
-
N. Ishii, K. Watashi, T. Hishiki, K. Goto, D. Inoue, M. Hijikata, T. Wakita, N. Kato, and K. Shimotohno Diverse effects of cyclosporine on hepatitis C virus strain replication Journal of Virology 80 2006 4510 4520
-
(2006)
Journal of Virology
, vol.80
, pp. 4510-4520
-
-
Ishii, N.1
Watashi, K.2
Hishiki, T.3
Goto, K.4
Inoue, D.5
Hijikata, M.6
Wakita, T.7
Kato, N.8
Shimotohno, K.9
-
39
-
-
84877258007
-
Treatment of HCV infection by targeting microRNA
-
H.L. Janssen, H.W. Reesink, E.J. Lawitz, S. Zeuzem, M. Rodriguez-Torres, K. Patel, A.J. van der Meer, A.K. Patick, A. Chen, Y. Zhou, R. Persson, B.D. King, S. Kauppinen, A.A. Levin, and M.R. Hodges Treatment of HCV infection by targeting microRNA The New England Journal of Medicine 368 2013 1685 1694
-
(2013)
The New England Journal of Medicine
, vol.368
, pp. 1685-1694
-
-
Janssen, H.L.1
Reesink, H.W.2
Lawitz, E.J.3
Zeuzem, S.4
Rodriguez-Torres, M.5
Patel, K.6
Van Der Meer, A.J.7
Patick, A.K.8
Chen, A.9
Zhou, Y.10
Persson, R.11
King, B.D.12
Kauppinen, S.13
Levin, A.A.14
Hodges, M.R.15
-
40
-
-
84881541827
-
EDP-546, a potent and novel cyclophilin inhibitor with favorable preclinical pharmacokinetic and safety profiles
-
1076A-1076A
-
L.J. Jiang, S. Liu, T.U. Phan, A.J. Polemeropoulos, M.H. Rhodin, C.M. Owens, X. Luo, K. Hoang, J. Long, X. Gao, G.Q. Wang, and Y.S. Or EDP-546, a potent and novel cyclophilin inhibitor with favorable preclinical pharmacokinetic and safety profiles Hepatology 56 2012 1076A-1076A
-
(2012)
Hepatology
, vol.56
-
-
Jiang, L.J.1
Liu, S.2
Phan, T.U.3
Polemeropoulos, A.J.4
Rhodin, M.H.5
Owens, C.M.6
Luo, X.7
Hoang, K.8
Long, J.9
Gao, X.10
Wang, G.Q.11
Or, Y.S.12
-
41
-
-
76349104162
-
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system
-
167-U116
-
C.T. Jones, M.T. Catanese, L.M.J. Law, S.R. Khetani, A.J. Syder, A. Ploss, T.S. Oh, J.W. Schoggins, M.R. MacDonald, S.N. Bhatia, and C.M. Rice Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system Nature Biotechnology 28 2010 167-U116
-
(2010)
Nature Biotechnology
, vol.28
-
-
Jones, C.T.1
Catanese, M.T.2
Law, L.M.J.3
Khetani, S.R.4
Syder, A.J.5
Ploss, A.6
Oh, T.S.7
Schoggins, J.W.8
Macdonald, M.R.9
Bhatia, S.N.10
Rice, C.M.11
-
42
-
-
24644483623
-
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA
-
C.L. Jopling, M. Yi, A.M. Lancaster, S.M. Lemon, and P. Sarnow Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA Science 309 2005 1577 1581
-
(2005)
Science
, vol.309
, pp. 1577-1581
-
-
Jopling, C.L.1
Yi, M.2
Lancaster, A.M.3
Lemon, S.M.4
Sarnow, P.5
-
46
-
-
84862652238
-
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice
-
K. Lacek, K. Vercauteren, K. Grzyb, M. Naddeo, L. Verhoye, M.P. Slowikowski, S. Fafi-Kremer, A.H. Patel, T.F. Baumert, A. Folgori, G. Leroux-Roels, R. Cortese, P. Meuleman, and A. Nicosia Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice Journal of Hepatology 57 2012 17 23
-
(2012)
Journal of Hepatology
, vol.57
, pp. 17-23
-
-
Lacek, K.1
Vercauteren, K.2
Grzyb, K.3
Naddeo, M.4
Verhoye, L.5
Slowikowski, M.P.6
Fafi-Kremer, S.7
Patel, A.H.8
Baumert, T.F.9
Folgori, A.10
Leroux-Roels, G.11
Cortese, R.12
Meuleman, P.13
Nicosia, A.14
-
47
-
-
74249112787
-
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
-
R.E. Lanford, E.S. Hildebrandt-Eriksen, A. Petri, R. Persson, M. Lindow, M.E. Munk, S. Kauppinen, and H. Orum Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection Science 327 2010 198 201
-
(2010)
Science
, vol.327
, pp. 198-201
-
-
Lanford, R.E.1
Hildebrandt-Eriksen, E.S.2
Petri, A.3
Persson, R.4
Lindow, M.5
Munk, M.E.6
Kauppinen, S.7
Orum, H.8
-
50
-
-
79951584235
-
Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy
-
E. Lawitz, E. Godofsky, R. Rouzier, T. Marbury, T. Nguyen, J. Ke, M. Huang, J. Praestgaard, D. Serra, and T.G. Evans Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy Antiviral Res. 89 3 2011 238 245
-
(2011)
Antiviral Res.
, vol.89
, Issue.3
, pp. 238-245
-
-
Lawitz, E.1
Godofsky, E.2
Rouzier, R.3
Marbury, T.4
Nguyen, T.5
Ke, J.6
Huang, M.7
Praestgaard, J.8
Serra, D.9
Evans, T.G.10
-
51
-
-
84873149944
-
Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication
-
Y. Li, T. Masaki, D. Yamane, D.R. McGivern, and S.M. Lemon Competing and noncompeting activities of miR-122 and the 5' exonuclease Xrn1 in regulation of hepatitis C virus replication Proceedings of the National Academy of Sciences of the United States of America 110 2013 1881 1886
-
(2013)
Proceedings of the National Academy of Sciences of the United States of America
, vol.110
, pp. 1881-1886
-
-
Li, Y.1
Masaki, T.2
Yamane, D.3
McGivern, D.R.4
Lemon, S.M.5
-
52
-
-
79953201904
-
MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR
-
Y.P. Li, J.M. Gottwein, T.K. Scheel, T.B. Jensen, and J. Bukh MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR Proceedings of the National Academy of Sciences of the United States of America 108 2011 4991 4996
-
(2011)
Proceedings of the National Academy of Sciences of the United States of America
, vol.108
, pp. 4991-4996
-
-
Li, Y.P.1
Gottwein, J.M.2
Scheel, T.K.3
Jensen, T.B.4
Bukh, J.5
-
54
-
-
84881553622
-
Curing a viral infection by targeting the host: The example of cyclophilin inhibitors
-
K. Lin, and P. Gallay Curing a viral infection by targeting the host: the example of cyclophilin inhibitors Antiviral research 2013
-
(2013)
Antiviral Research
-
-
Lin, K.1
Gallay, P.2
-
55
-
-
67449093865
-
Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex
-
Z. Liu, F. Yang, J.M. Robotham, and H. Tang Critical role of cyclophilin A and its prolyl-peptidyl isomerase activity in the structure and function of the hepatitis C virus replication complex Journal of Virology 83 2009 6554 6565
-
(2009)
Journal of Virology
, vol.83
, pp. 6554-6565
-
-
Liu, Z.1
Yang, F.2
Robotham, J.M.3
Tang, H.4
-
56
-
-
33748687426
-
NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon
-
S. Ma, J.E. Boerner, C. TiongYip, B. Weidmann, N.S. Ryder, M.P. Cooreman, and K. Lin NIM811, a cyclophilin inhibitor, exhibits potent in vitro activity against hepatitis C virus alone or in combination with alpha interferon Antimicrobial Agents and Chemotherpy 50 2006 2976 2982
-
(2006)
Antimicrobial Agents and Chemotherpy
, vol.50
, pp. 2976-2982
-
-
Ma, S.1
Boerner, J.E.2
Tiongyip, C.3
Weidmann, B.4
Ryder, N.S.5
Cooreman, M.P.6
Lin, K.7
-
57
-
-
74049120411
-
The global spread of hepatitis C virus 1a and 1b: A phylodynamic and phylogeographic analysis
-
G. Magiorkinis, E. Magiorkinis, D. Paraskevis, S.Y. Ho, B. Shapiro, O.G. Pybus, J.P. Allain, and A. Hatzakis The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis PLoS Medicine 6 2009 e1000198
-
(2009)
PLoS Medicine
, vol.6
, pp. 1000198
-
-
Magiorkinis, G.1
Magiorkinis, E.2
Paraskevis, D.3
Ho, S.Y.4
Shapiro, B.5
Pybus, O.G.6
Allain, J.P.7
Hatzakis, A.8
-
58
-
-
73849098682
-
Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor
-
D. Masson, M. Koseki, M. Ishibashi, C.J. Larson, S.G. Miller, B.D. King, and A.R. Tall Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor Arteriosclerosis, Thrombosis, and Vascular Biology 29 2009 2054 U2170
-
(2009)
Arteriosclerosis, Thrombosis, and Vascular Biology
, vol.29
-
-
Masson, D.1
Koseki, M.2
Ishibashi, M.3
Larson, C.J.4
Miller, S.G.5
King, B.D.6
Tall, A.R.7
-
59
-
-
84881549497
-
Bc556, a potent, pan-genotypic, high barrier to resistance, second generation cyclophilin inhibitor for treatment of chronic Hcv infection
-
S328-S328
-
S.J. Moss, J.A. Garcia-Rivera, P. Leyssen, N. Coates, T. Foster, S. Kendrew, M. Nur-E-Alam, A.E. Stanley, D. Suthar, T. Warneck, J. Neyts, P. Gallay, B. Wilkinson, and M.A. Gregory Bc556, a potent, pan-genotypic, high barrier to resistance, second generation cyclophilin inhibitor for treatment of chronic Hcv infection Journal of Hepatology 56 2012 S328-S328
-
(2012)
Journal of Hepatology
, vol.56
-
-
Moss, S.J.1
Garcia-Rivera, J.A.2
Leyssen, P.3
Coates, N.4
Foster, T.5
Kendrew, S.6
Nur-E-Alam, M.7
Stanley, A.E.8
Suthar, D.9
Warneck, T.10
Neyts, J.11
Gallay, P.12
Wilkinson, B.13
Gregory, M.A.14
-
60
-
-
77955873433
-
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection
-
A.J. Muir, M.L. Shiffinan, A. Zaman, B. Yoffe, A. de la Torre, S. Flamm, S.C. Gordon, P. Marotta, J.M. Vierling, J.C. Lopez-Talavera, K. Byrnes-Blake, D. Fontana, J. Freeman, T. Gray, D. Hausman, N.N. Hunder, and E. Lawitz Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology 52 2010 822 832
-
(2010)
Hepatology
, vol.52
, pp. 822-832
-
-
Muir, A.J.1
Shiffinan, M.L.2
Zaman, A.3
Yoffe, B.4
De La Torre, A.5
Flamm, S.6
Gordon, S.C.7
Marotta, P.8
Vierling, J.M.9
Lopez-Talavera, J.C.10
Byrnes-Blake, K.11
Fontana, D.12
Freeman, J.13
Gray, T.14
Hausman, D.15
Hunder, N.N.16
Lawitz, E.17
-
61
-
-
10744223246
-
Specific inhibition of hepatitis C virus replication by cyclosporin A
-
M. Nakagawa, N. Sakamoto, N. Enomoto, Y. Tanabe, N. Kanazawa, T. Koyama, M. Kurosaki, S. Maekawa, T. Yamashiro, C.H. Chen, Y. Itsui, S. Kakinuma, and M. Watanabe Specific inhibition of hepatitis C virus replication by cyclosporin A Biochemical and Biophysical Research Communications 313 2004 42 47
-
(2004)
Biochemical and Biophysical Research Communications
, vol.313
, pp. 42-47
-
-
Nakagawa, M.1
Sakamoto, N.2
Enomoto, N.3
Tanabe, Y.4
Kanazawa, N.5
Koyama, T.6
Kurosaki, M.7
Maekawa, S.8
Yamashiro, T.9
Chen, C.H.10
Itsui, Y.11
Kakinuma, S.12
Watanabe, M.13
-
62
-
-
84887478350
-
Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance
-
Amsterdam. Abstract 1213
-
Owens CM, R.M., Polemeropoulos A, Long J, Wang G, Jiang L, Or YS 2013. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance. Cyclophilin Inhibitor EDP-546 is a Potential Cornerstone Drug for Use in Combination with NS5A and Protease Inhibitors Due to its High Barrier to HCV Resistance, 48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013), Amsterdam. Abstract 1213.
-
(2013)
48th Annual Meeting of the European Association for the Study of the Liver (EASL 2013)
-
-
Owens, C.M.1
Polemeropoulos, A.2
Long, J.3
Wang, G.4
Jiang, L.5
Or, Y.S.6
-
63
-
-
33646015668
-
The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro
-
J. Paeshuyse, A. Kaul, E. De Clercq, B. Rosenwirth, J.M. Dumont, P. Scalfaro, R. Bartenschlager, and J. Neyts The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro Hepatology 43 2006 761 770
-
(2006)
Hepatology
, vol.43
, pp. 761-770
-
-
Paeshuyse, J.1
Kaul, A.2
De Clercq, E.3
Rosenwirth, B.4
Dumont, J.M.5
Scalfaro, P.6
Bartenschlager, R.7
Neyts, J.8
-
64
-
-
84880304436
-
Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: Final results from VITAL-1 study
-
J.M. Pawlotsky, S.K. Sarin, G.R. Foster, C.Y. Peng, J. Rasenack, R. Flisiak, T. Piratvisuth, H. Wedemeyer, W.L. Chuang, W. Zhang, and N.V. Naoumov Alisporivir plus Ribavirin achieves high rates of sustained HCV clearance (SVR24) as interferon (IFN)-free or IFN-add-on regimen in treatment-naive patients with HCV GT2 or GT3: final results from VITAL-1 study Hepatology 56 2012 309A 310A
-
(2012)
Hepatology
, vol.56
-
-
Pawlotsky, J.M.1
Sarin, S.K.2
Foster, G.R.3
Peng, C.Y.4
Rasenack, J.5
Flisiak, R.6
Piratvisuth, T.7
Wedemeyer, H.8
Chuang, W.L.9
Zhang, W.10
Naoumov, N.V.11
-
65
-
-
84880353282
-
Response of hepatitis C virus to long-term passage in the presence of alpha interferon: Multiple mutations and a common phenotype
-
C. Perales, N.M. Beach, I. Gallego, M.E. Soria, J. Quer, J.I. Esteban, C. Rice, E. Domingo, and J. Sheldon Response of hepatitis C virus to long-term passage in the presence of alpha interferon: multiple mutations and a common phenotype Journal of virology 87 2013 7593 7607
-
(2013)
Journal of Virology
, vol.87
, pp. 7593-7607
-
-
Perales, C.1
Beach, N.M.2
Gallego, I.3
Soria, M.E.4
Quer, J.5
Esteban, J.I.6
Rice, C.7
Domingo, E.8
Sheldon, J.9
-
67
-
-
34547913440
-
Cellular cofactors affecting hepatitis C virus infection and replication
-
G. Randall, M. Panis, J.D. Cooper, T.L. Tellinghuisen, K.E. Sukhodolets, S. Pfeffer, M. Landthaler, P. Landgraf, S. Kan, B.D. Lindenbach, M. Chien, D.B. Weir, J.J. Russo, J. Ju, M.J. Brownstein, R. Sheridan, C. Sander, M. Zavolan, T. Tuschl, and C.M. Rice Cellular cofactors affecting hepatitis C virus infection and replication Proceedings of the National Academy of Sciences of the United States of America 104 2007 12884 12889
-
(2007)
Proceedings of the National Academy of Sciences of the United States of America
, vol.104
, pp. 12884-12889
-
-
Randall, G.1
Panis, M.2
Cooper, J.D.3
Tellinghuisen, T.L.4
Sukhodolets, K.E.5
Pfeffer, S.6
Landthaler, M.7
Landgraf, P.8
Kan, S.9
Lindenbach, B.D.10
Chien, M.11
Weir, D.B.12
Russo, J.J.13
Ju, J.14
Brownstein, M.J.15
Sheridan, R.16
Sander, C.17
Zavolan, M.18
Tuschl, T.19
Rice, C.M.20
more..
-
68
-
-
84878499077
-
The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A
-
Reiss, S., Harak, C., Romero-Brey, I., Radujkovic, D., Klein, R., Ruggieri, A., Rebhan, I., Bartenschlager, R., Lohmann, V., 2013. The Lipid Kinase Phosphatidylinositol-4 Kinase III Alpha Regulates the Phosphorylation Status of Hepatitis C Virus NS5A. Plos Pathog 9.
-
(2013)
Plos Pathog
, vol.9
-
-
Reiss, S.1
Harak, C.2
Romero-Brey, I.3
Radujkovic, D.4
Klein, R.5
Ruggieri, A.6
Rebhan, I.7
Bartenschlager, R.8
Lohmann, V.9
-
69
-
-
82455184210
-
Imo-2125, a Tlr9 Agonist, Induces Immune Responses Which Correlate with Reductions in Viral Load in Null Responder Hcv Patients
-
336A-336A
-
M. Rodriguez-Torres, R.H. Ghalib, S.C. Gordon, E. Lawitz, K. Patel, R. Pruitt, A.M. Sheikh, R.D. Arbeit, A.S. Bexon, E.R. Kandimalla, M. Precopio, T. Sullivan, A.J. Muir, and J.G. McHutchison Imo-2125, a Tlr9 Agonist, Induces Immune Responses Which Correlate with Reductions in Viral Load in Null Responder Hcv Patients Hepatology 52 2010 336A-336A
-
(2010)
Hepatology
, vol.52
-
-
Rodriguez-Torres, M.1
Ghalib, R.H.2
Gordon, S.C.3
Lawitz, E.4
Patel, K.5
Pruitt, R.6
Sheikh, A.M.7
Arbeit, R.D.8
Bexon, A.S.9
Kandimalla, E.R.10
Precopio, M.11
Sullivan, T.12
Muir, A.J.13
McHutchison, J.G.14
-
70
-
-
84880309916
-
Understanding the hepatitis C virus life cycle paves the way for highly effective therapies
-
T.K.H. Scheel, and C.M. Rice Understanding the hepatitis C virus life cycle paves the way for highly effective therapies Nat Med 19 2013 837 849
-
(2013)
Nat Med
, vol.19
, pp. 837-849
-
-
Scheel, T.K.H.1
Rice, C.M.2
-
71
-
-
84856367312
-
Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex
-
T. Shimakami, D. Yamane, R.K. Jangra, B.J. Kempf, C. Spaniel, D.J. Barton, and S.M. Lemon Stabilization of hepatitis C virus RNA by an Ago2-miR-122 complex Proceedings of the National Academy of Sciences of the United States of America 109 2012 941 946
-
(2012)
Proceedings of the National Academy of Sciences of the United States of America
, vol.109
, pp. 941-946
-
-
Shimakami, T.1
Yamane, D.2
Jangra, R.K.3
Kempf, B.J.4
Spaniel, C.5
Barton, D.J.6
Lemon, S.M.7
-
72
-
-
33748455338
-
Type i interferons in host defense
-
D.B. Stetson, and R. Medzhitov Type I interferons in host defense Immunity 25 2006 373 381
-
(2006)
Immunity
, vol.25
, pp. 373-381
-
-
Stetson, D.B.1
Medzhitov, R.2
-
73
-
-
78649633787
-
Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors
-
A.J. Syder, H. Lee, M.B. Zeisel, J. Grove, E. Soulier, J. Macdonald, S. Chow, J. Chang, T.F. Baumert, J.A. McKeating, J. McKelvy, and F. Wong-Staal Small molecule scavenger receptor BI antagonists are potent HCV entry inhibitors Journal of Hepatology 54 2011 48 55
-
(2011)
Journal of Hepatology
, vol.54
, pp. 48-55
-
-
Syder, A.J.1
Lee, H.2
Zeisel, M.B.3
Grove, J.4
Soulier, E.5
Macdonald, J.6
Chow, S.7
Chang, J.8
Baumert, T.F.9
McKeating, J.A.10
McKelvy, J.11
Wong-Staal, F.12
-
74
-
-
84868143510
-
Evaluation of Phosphatidylinositol-4-Kinase III alpha as a Hepatitis C Virus Drug Target
-
F.H. Vaillancourt, M. Brault, L. Pilote, N. Uyttersprot, E.T. Gaillard, J.H. Stoltz, B.L. Knight, L. Pantages, M. McFarland, S. Breitfelder, T.T. Chiu, L. Mahrouche, A.M. Faucher, M. Cartier, M.G. Cordingley, R.C. Bethell, H.P. Jiang, P.W. White, and G. Kukolj Evaluation of Phosphatidylinositol-4-Kinase III alpha as a Hepatitis C Virus Drug Target Journal of virology 86 2012 11595 11607
-
(2012)
Journal of Virology
, vol.86
, pp. 11595-11607
-
-
Vaillancourt, F.H.1
Brault, M.2
Pilote, L.3
Uyttersprot, N.4
Gaillard, E.T.5
Stoltz, J.H.6
Knight, B.L.7
Pantages, L.8
McFarland, M.9
Breitfelder, S.10
Chiu, T.T.11
Mahrouche, L.12
Faucher, A.M.13
Cartier, M.14
Cordingley, M.G.15
Bethell, R.C.16
Jiang, H.P.17
White, P.W.18
Kukolj, G.19
-
75
-
-
77951022934
-
The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A
-
H. Waller, U. Chatterji, P. Gallay, T. Parkinson, and P. Targett-Adams The use of AlphaLISA technology to detect interaction between hepatitis C virus-encoded NS5A and cyclophilin A J Virol Methods 165 2010 202 210
-
(2010)
J Virol Methods
, vol.165
, pp. 202-210
-
-
Waller, H.1
Chatterji, U.2
Gallay, P.3
Parkinson, T.4
Targett-Adams, P.5
-
76
-
-
0142182744
-
Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes
-
K. Watashi, M. Hijikata, M. Hosaka, M. Yamaji, and K. Shimotohno Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes Hepatology 38 2003 1282 1288
-
(2003)
Hepatology
, vol.38
, pp. 1282-1288
-
-
Watashi, K.1
Hijikata, M.2
Hosaka, M.3
Yamaji, M.4
Shimotohno, K.5
-
77
-
-
59849121683
-
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells
-
J. Witteveldt, M.J. Evans, J. Bitzegeio, G. Koutsoudakis, A.M. Owsianka, A.G.N. Angus, Z.Y. Keck, S.K.H. Foung, T. Pietschmann, C.M. Rice, and A.H. Patel CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells J Gen Virol 90 2009 48 58
-
(2009)
J Gen Virol
, vol.90
, pp. 48-58
-
-
Witteveldt, J.1
Evans, M.J.2
Bitzegeio, J.3
Koutsoudakis, G.4
Owsianka, A.M.5
Angus, A.G.N.6
Keck, Z.Y.7
Foung, S.K.H.8
Pietschmann, T.9
Rice, C.M.10
Patel, A.H.11
-
78
-
-
56149118610
-
Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production
-
W. Yang, B.L. Hood, S.L. Chadwick, S. Liu, S.C. Watkins, G. Luo, T.P. Conrads, and T. Wang Fatty acid synthase is up-regulated during hepatitis C virus infection and regulates hepatitis C virus entry and production Hepatology 48 2008 1396 1403
-
(2008)
Hepatology
, vol.48
, pp. 1396-1403
-
-
Yang, W.1
Hood, B.L.2
Chadwick, S.L.3
Liu, S.4
Watkins, S.C.5
Luo, G.6
Conrads, T.P.7
Wang, T.8
-
79
-
-
79960443884
-
PEGYLATED INTERFERON-LAMBDA (PEGIFN-lambda) SHOWS SUPERIOR VIRAL RESPONSE with IMPROVED SAFETY and TOLERABILITY VERSUS PEGIFN alpha-2A in HCV PATIENTS (G1/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
-
S. Zeuzem, S. Arora, B. Bacon, T. Box, M. Charlton, M. Diago, D. Dieterich, R.E. Mur, G. Everson, M. Fallon, P. Ferenci, R. Flisiak, J. George, R. Ghalib, N. Gitlin, A. Gladysz, S. Gordon, S. Greenbloom, T. Hassanein, I. Jacobson, L. Jeffers, K. Kowdley, E. Lawitz, S. Lee, B. Leggett, S. Lueth, D. Nelson, P. Pockros, M. Rodriguez-Torres, V. Rustgi, L. Serfaty, M. Sherman, M. Shiffman, R. Sola, M. Sulkowski, H. Vargas, J. Vierling, B. Yoffe, L. Ishak, D. Fontana, D. Xu, J. Lester, T. Gray, A. Horga, J. Hillson, E. Ramos, J.C. Lopez-Talavera, A. Muir, and E.S. Grp PEGYLATED INTERFERON-LAMBDA (PEGIFN-lambda) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFN alpha-2A IN HCV PATIENTS (G1/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12 Journal of Hepatology 54 2011 S538 S539
-
(2011)
Journal of Hepatology
, vol.54
-
-
Zeuzem, S.1
Arora, S.2
Bacon, B.3
Box, T.4
Charlton, M.5
Diago, M.6
Dieterich, D.7
Mur, R.E.8
Everson, G.9
Fallon, M.10
Ferenci, P.11
Flisiak, R.12
George, J.13
Ghalib, R.14
Gitlin, N.15
Gladysz, A.16
Gordon, S.17
Greenbloom, S.18
Hassanein, T.19
Jacobson, I.20
Jeffers, L.21
Kowdley, K.22
Lawitz, E.23
Lee, S.24
Leggett, B.25
Lueth, S.26
Nelson, D.27
Pockros, P.28
Rodriguez-Torres, M.29
Rustgi, V.30
Serfaty, L.31
Sherman, M.32
Shiffman, M.33
Sola, R.34
Sulkowski, M.35
Vargas, H.36
Vierling, J.37
Yoffe, B.38
Ishak, L.39
Fontana, D.40
Xu, D.41
Lester, J.42
Gray, T.43
Horga, A.44
Hillson, J.45
Ramos, E.46
Lopez-Talavera, J.C.47
Muir, A.48
Grp, E.S.49
more..
-
80
-
-
84863012788
-
Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination with Other Hepatitis C Virus Antivirals
-
H.H. Zhu, F. Wong-Staal, H. Lee, A. Syder, J. McKelvy, R.T. Schooley, and D.L. Wyles Evaluation of ITX 5061, a Scavenger Receptor B1 Antagonist: Resistance Selection and Activity in Combination With Other Hepatitis C Virus Antivirals Journal of Infectious Diseases 205 2012 656 662
-
(2012)
Journal of Infectious Diseases
, vol.205
, pp. 656-662
-
-
Zhu, H.H.1
Wong-Staal, F.2
Lee, H.3
Syder, A.4
McKelvy, J.5
Schooley, R.T.6
Wyles, D.L.7
-
81
-
-
0027071803
-
Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition
-
L.D. Zydowsky, F.A. Etzkorn, H.Y. Chang, S.B. Ferguson, L.A. Stolz, S.I. Ho, and C.T. Walsh Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition Protein Science 1 1992 1092 1099
-
(1992)
Protein Science
, vol.1
, pp. 1092-1099
-
-
Zydowsky, L.D.1
Etzkorn, F.A.2
Chang, H.Y.3
Ferguson, S.B.4
Stolz, L.A.5
Ho, S.I.6
Walsh, C.T.7
|